The CEO of obesity drug manufacturer Novo Nordisk and heads of other Danish companies were expected to discuss preparations ...

The head of Ozempic maker Novo Nordisk A/S is among business executives who are meeting the Danish prime minister to discuss ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Denmark’s Prime Minister Mette Frederiksen has called the country’s business leaders to a meeting on Thursday after US ...

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

Hims & Hers Health ( HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth ...

Investing.com -- Bernstein analysts highlighted a more attractive valuation for Novo Nordisk (NYSE: NVO) following recent ...